
Opinion|Videos|December 18, 2024
Case 3: Nonmetastatic Castration-Sensitive Prostate Cancer With Biochemical Recurrence
Panelists discuss how the management of nonmetastatic castration-sensitive prostate cancer with biochemical recurrence involves careful monitoring and the potential use of novel therapies, such as androgen receptor inhibitors, to delay progression and improve patient outcomes.
Advertisement
Episodes in this series
Advertisement
Latest CME
Advertisement
Advertisement






